\
&
Contact us
\
&
Contact us
Published on | 10 months ago
ProgrammesThere are 3 attachments connected to this article.
Attachments are only accessible for people with an account on the NCP Flanders website.
Headquarters Supreme Allied Commander Transformation (HQ SACT) is issuing this Request for Information (RFI) in order to engage with industry and Academia on future Next Generation (NG) Wireless (other than SATCOM) Capabilities.
The intention is to evaluate what could be immediately available, the art-of-the-possible and state-of-the-art with respect to systems, products, services, technologies, and methodologies pertaining to NG Wireless. This will support NATO Governance decision making on Common Funded Capability Delivery.
If you would like to respond, your answers are expected on 14/05/2025 (09h am EST) by email.
May we ask you to inform the Directorate of Aviation and Defence if you intend to answer this RFI.
email: dirk.ghijsens@economie.fgov.be ; sander.drieghe@economie.fgov.be
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
